In this episode of the DeviceTalks Weekly Podcast, host Tom Salemi is reassured by his conversation with Joe Catanese, CEO of Calyxo, a urology startup that has developed a system designed to simplify kidney stone removal.

Catanese previously helped build Neotract, a urology startup that was acquired by Teleflex for more than $1 billion. Now, he's leading another potential gamechanger and may have his sights set on an IPO.

Speaking of gamechangers, HistoSonics continues to shatter fundraising expectations. The company recently completed a financing round that valued it at $3.75 billion. In this week's FOMO interview, HistoSonics President and CEO Mike Blue speaks with MassDevice Editor Chris Newmarker during a keynote conversation at DeviceTalks Minnesota.

In this excerpt, Blue reflects on the company's first major fundraising round, which attracted high-profile investors including Jeff Bezos and Peter Thiel, and shares his perspective on just how large the opportunity for histotripsy could become.

But first, Tom and Jim Hammerand, managing editor of Medical Design & Outsourcing, discuss AI—or LLMs, or whatever term you prefer. Is the hype beginning to fade? And what should the industry make of the recent announcement from Midjourney Medical?

***

Enjoy the show? Follow DeviceTalks Weekly on all major podcast players + Follow us on YouTube.com/@DeviceTalks to ensure you never miss an episode.

Want access to the complete DeviceTalks Podcast Network (DTPN)? Follow us today at https://devicetalks.castos.com/subscribe

Chapters

(00:05:29) - AI Talk with Jim Hammerand, managing editor, Medical Design & Outsourcing
(00:24:46) - DeviceTalks Minnesota interview excerpt - Mike Blue, CEO and President, Histosonics
(00:41:44) - Keynote Interview with Joe Catanese, CEO and President, Calyxo

Can Calyxo CEO Catanese Lead New Company Down Familiar Tract to Build Another Urology Powerhouse

DeviceTalks Podcast Network

Can Calyxo CEO Catanese Lead New Company Down Familiar Tract to Build Another Urology Powerhouse